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Abstract 
Background 
Subjective reports of insomnia and hypersomnia are common in bipolar disorder (BD).  It is unclear 
to what extent these relate to underlying circadian rhythm disturbance (CRD). In this study we aimed 
to objectively assess sleep and circadian rhythm in a cohort of patients with BD compared to 
matched controls. 
Methods 
46 patients with BD and 42 controls had comprehensive sleep/circadian rhythm assessment with 
respiratory sleep studies, prolonged accelerometry over 3 weeks, sleep questionnaires and diaries, 
melatonin levels, alongside mood, psychosocial functioning and quality of life (QoL) questionnaires. 
Results 
23 (50%) of patients with BD had abnormal sleep, of whom 12 (52%) had CRD and 29% had 
obstructive sleep apnoea.  Patients with abnormal sleep had lower 24 hour melatonin secretion 
compared to controls and patients with normal sleep.  Abnormal sleep/CRD in BD was associated 
with impaired functioning and worse QoL. 
Conclusions 
BD is associated with high rates of abnormal sleep and CRD.  The association between these 
disorders, mood and functioning, and the direction of causality, warrants further investigation. 
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Introduction 
Subjective reports of various types of sleep disturbance are described in all phases of bipolar 
disorder (BD), including remission(Harvey, 2008, Harvey et al., 2005, Kanady et al., 2015, Kaplan et 
al., 2011, Ng et al., 2015) but with substantial variability in prevalence between studies.  Meta-
analyses of studies objectively estimating sleep variables in remitted BD patients demonstrated 
prolonged total sleep time (TST), increased wakenings after sleep onset greater variability of sleep-
wake variables and reduced sleep efficiency (Geoffroy et al., 2014, Ng et al., 2015). These meta-
analyses highlighted that there has also been little consistency in the way sleep and circadian rhythm 
has been measured and assessed.  Studies have used a range of actiwatches and algorithms for 
calculating sleep and wake estimates and utilised variable recording periods making comparisons 
across studies challenging.  There is a need for methodological improvements, including longer 
recordings to allow improved analysis of circadian rhythm measures.  Thus it is currently unknown 
what proportion of sleep disorder relates to a circadian rhythm disorder (CRD). Furthermore, none 
of the published actigraphy studies in BD have performed respiratory sleep studies to screen for 
primary sleep disorders, such as obstructive sleep apnoea (OSA), that may additionally contribute to 
hypersomnia and sleep fragmentation.  The aim of this study was to describe the different 
sleep/wake phenotypes in an opportunistic cohort of patients with BD and age matched healthy 
controls with a comprehensive battery of objective and subjective assessments of sleep and 
circadian variables, including urinary melatonin levels and respiratory sleep studies analysis.  
 
Method 
Participants 
The study was approved by the National Research Ethics Service Committee North East - Newcastle 
& North Tyneside.  Outpatients with BD type I or II, in any mood state, were recruited from a 
research database, patient support groups, and NHS services in the North East of England. Healthy 
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controls, matched by age and gender, were recruited from Newcastle University, local volunteer 
databases and hospital staff and their families.  All participants provided written informed consent 
before taking part in the research.  Participants were 18 to 65 years, fluent in English and able to 
provide consent. Exclusion criteria were; Verbal IQ < 90 assessed with National Adult Reading Test 
(NART)(Nelson, 1982), any significant medical or neurological disorder that might interfere with 
sleep or cognition, current alcohol or substance misuse disorder (defined with DSM IV 
criteria(American Psychiatric Association, 2000), current shift work and previous significant head 
injury. A BD diagnosis meeting DSM-IV criteria was confirmed using the Mini International 
Neuropsychological Interview (MINI)(Sheehan et al., 1998). Patients with BD were excluded if they 
had had any changes to their psychotropic medication in the previous 4 weeks. Exclusion criteria for 
controls were personal or first degree relative history of a DSM IV Axis I disorder as determined by 
clinical history, prescribed psychotropic medications and any known sleep disorder. Additionally 
controls had to be psychiatrically well, confirmed by MINI interview, have a Hamilton Depression 
rating scale score (HAMD17) score <7, a Young Mania Rating Scale score (YMRS) <5, a Pittsburgh 
sleep quality index (PSQI) <5 and Epworth sleepiness scale (ESS) score <10.  
Overall study design 
The study was cross-sectional, with participants assessed over a three week period. 
Psychiatric Symptoms and Subjective Sleep Assessments 
Participants were assessed on days 1 and 21. A comprehensive battery of questionnaires and rating 
scales were used to assess mood, anxiety and functioning.  These included: the 17 item GRID-HAMD 
(Williams et al., 2008), Beck Depression Inventory (BDI) (Beck et al., 1961), YMRS (Young et al., 
1978), the State and Trait Anxiety Inventory (STAI) (Spielberger et al., 1983), the Functioning 
Assessment Short Test (FAST) (Rosa et al., 2007).  Quality of life (QoL) was assessed with the BD 
specific scale, the QoL.BD (Michalak and Murray, 2010).  Subjective sleep and circadian rhythm was 
assessed using: the Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) (Giglio 
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et al., 2009), the PSQI where a score > 5 indicates clinically significant poor sleep quality (Buysse et 
al., 1989) and the ESS where a score > 10 indicates excessive daytime sleepiness (Johns, 1991). A 
short version of the morningness/eveningness questionnaire (Horne and Ostberg, 1976) was also 
used on day 1 of the study to assess chronotype. All medications used by the patients in the BD 
group were recorded.  
Assessment for sleep apnoea 
A single night of home partial polysomnography, using the Embletta Gold Polygraphy System (Embla 
Systems, Bloomfield, USA), was used to screen for sleep apnoea. Respiratory events were scored 
according to the standard criteria of the American Association of Sleep Medicine (AASM) (Kushida et 
al., 2005) and the apnoea hypopnoea index (AHI) and oxygen desaturation index (ODI) derived. An 
AHI of > 5/hr was considered abnormal and indicative of sleep apnoea. Severity was defined as mild 
(AHI 5-15), moderate (AHI 15 – 30) or severe (AHI >30).  
Assessment for Restless Leg Syndrome (RLS).  
Participants completed the Restless Legs Syndrome Rating Scale to assess for the presence and 
severity of RLS (Walters et al., 2003). This scale includes 10 questions each scoring 0-4 with a score 
of 1-10 representing mild RLS, 11-20 moderate RLS, 21-30 severe RLS and 31-40 very severe RLS.  
Assessment of sleep wake cycle 
Subjects wore a triaxial wrist accelerometer (GENEActiv; Activinsights) on their non-dominant wrist 
for all 21 days of the study and completed a daily sleep log recording lights out, out of bed time and 
any daytime naps. Unlike older actigraphs which record movement in brand specific activity counts 
modern accelerometers record high resolution data in universal units of gravitational acceleration 
(raw accelerometry). These data can be analysed to estimate both physical activity and sleep. Data 
recorded in SI units rather than brand specific activity counts allows for the comparison of data 
recorded from any brand of device which records in SI units and therefore allows direct comparisons 
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between studies and the pooling of data (te Lindert and Van Someren, 2013). In this study the 
accelerometer was set to sample at 30 Hz in order that the battery would continuously record for a 
period of at least 21 days. The raw accelerometer data was analysed using an open source R package 
sleep detection algorithm, GGIR, that has already demonstrated a high sensitivity and specificity to 
detect periods of sleep (van Hees et al., 2015). This algorithm uses a novel method of accelerometer 
derived arm angle to detect sleep.  Estimated arm angles are averaged per 5 second epoch and used 
to assess change in arm angle between successive 5 second epochs. Periods of time during which 
there is no change in arm angle larger than 5° over at least 5 minutes are classified as bouts of 
sustained inactivity, or potential sleep periods. The algorithm utilises the sleep log to distinguish 
nocturnal sleep from daytime naps. The following variables were derived: sleep onset time, sleep 
offset time, TST, time in bed (TIB), sleep efficiency (defined as TST/TIB) and mean 24 hour sleep 
duration (defined as nocturnal sleep plus daytime naps). Intra-subject variability in sleep variables 
was defined by the between night standard deviation over the assessment period for individual 
participants. Correlation analysis was performed to check agreement between sleep logs and 
accelerometer derived sleep variables. The relative amplitude between day and night activity was 
calculated from mean acceleration recorded in milli gravitational units (milli-g) during the least 
active 5 hours (L5) and most active 10 hours (M10) according to previously published methods (Van 
Someren et al., 1999). Using both accelerometry derived sleep estimates and the visual sleep wake 
actograms produced by the algorithm participants were then identified as normal sleepers (6-10 
hours sleep within 24 hours with a regular sleep wake cycle), short sleepers (<6 hours nocturnal 
sleep), long sleep (>10 hours sleep within 24 hours) and circadian rhythm disturbance  evidenced by 
either a delayed sleep phase (habitual sleep onset after 2am), advanced sleep phase, an irregular 
sleep wake pattern (three to four periods of sleep but no consolidated overnight period) or a non24 
hour pattern in keeping with the circadian rhythm types within the International Classification of 
Sleep Disorder – 3rd edition (ICSD-3) (American Academy of Sleep Medicine, 2014). Therefore those 
sleeping >3 hours outside of societal norms eg habitual sleep time 3am, or rise time that varied day 
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to day by > 3hours in the absence of shift work. Those sleeping less than 6 hours or > 10 hours were 
also defined as abnormally short or long sleepers again based on the normative sleep period defined 
within ICSD3. 
Melatonin Measurement 
To further explore possible mechanisms of circadian dysfunction 6-sulphatoxymelatonin (aMT6S) 
was measured. This metabolite of melatonin, was measured in urine over a 48 hour period, once 
during the first week of the study period and once during the third week of the study period with 
analysis as per previous published protocols (Wulff et al., 2006).  
In brief, participants recorded the time of their last toilet visit and then passed each subsequent full 
volume of urine into a measuring jug at 4 hour intervals (or 8 hours over night) for the next 48 hours. 
The total volume of urine and exact clock time it was passed were recorded and a 5ml sample taken 
and stored at -20⁰C before being sent for analysis by radioimmunoassay to determin aMT6S 
concentrations (Aldhous and Arendt, 1988). 
Statistical analysis 
All statistical analyses were performed using IBM SPSS statistical package version 22.  Normality of 
distribution of data was tested using the Shapiro-Wilk test.  Log10 or square root transformations 
were used where necessary to normalise the data.  Parametric tests were used unless the data 
remained non-normally distributed despite transformation when equivalent non-parametric tests 
were used.  A significance threshold of p< 0.05 was used for all analyses. The aMT6s profiles were 
evaluated using cosinor analysis, based on the least square approximation of the time series using a 
cosine function with a period of 24 hours (Minors and Waterhouse, 1988) and the following 
parameters obtained: acrophase time: time of the peak aMT6s concentration or maximum of the 
fitted cosinor function; mesor: mean aMT6s value for all the samples included in the cosinor 
analysis; and amplitude: difference between the mesor and the peak aMT6s concentrations. Two 
estimates of ‘‘goodness of fit’’ were used to determine the validity of the cosinor-derived  indices: (i) 
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the percentage rhythm or percentage data variability accounted for by the cosine curve: 100% 
rhythm = all data points fall on the cosine curve; 0% rhythm = none of the data points falls on the 
cosine curve and (ii) the likelihood of the data points fitting a straight line as opposed to a cosine 
curve, expressed as a p value. Data were considered acceptable if the % rhythm equalled or 
exceeded 50 and the cosinor fit was significant at the 95% level (p<0.05) (Minors and Waterhouse, 
1988). 
 
Results 
Participants 
Eighty eight participants, 46 with BD (16 BD I and 30 BDII) and 42 controls, completed the study 
protocol and provided accelerometer data (mean 19.7 (SD 3.0) days). Table 1 shows the participant 
characteristics. Groups did not differ significantly with regard to age or gender but participants with 
BD had a greater body mass index (BMI), were more likely to be unemployed, and scored more 
highly on mood and anxiety ratings and lower on quality of life. Twenty one participants with BD 
scored > 8 on the HAMD17 (range 8 -35), but none of the patients were considered clinically to be 
manic or hypomanic for the duration of the study (YMRS range 0-10).   
Subjective description of sleep 
On the PSQI, patients with BD scored on average 6.4 points higher than the healthy controls (Table 
1), with 30 (65.2%) scoring ≥5, indicative of some form of sleep disturbance (Note that a PSQI of ≥5 
was an exclusion criteria for healthy controls). Many patients with BD described subjective problems 
with their sleep.  Their average score across the three HAMD17 sleep items was 2.13 (SD 1.9), with 12 
(26.1%) of patients scoring ≥4.  The ESS, validated for identifying excessive daytime sleepiness, was 
>10 in 9 BD patients.   In terms of chronotype, the BD group contained more participants with an 
evening preference than the control group but the difference was not statistically significant (chi 
squared; 4.449, p=0.108). 
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Sleep Apnoea 
Forty one of 46 participants with BD and 40 of the 42 controls completed the overnight partial 
polysomnography providing good quality respiratory data. Significantly more participants with BD 
than controls had OSA (BD n=12 (29%), controls n=4 (10%), chi squared; 4.742, p=0.029). Four 
participants with BD had moderately severe OSA (AHI 15-30) but no participant in either group had 
severe sleep apnoea (AHI > 30). One participant with BD was already on continuous positive airways 
pressure (CPAP) treatment for known OSA and was therefore counted as AHI < 5 and hence with 
‘normal’ sleep. The BD patients with OSA were older than normal BD sleepers 44 years vs 51 years 
p=0.054. 
Two participants with BD with moderately severe OSA went on to successfully start treatment with 
CPAP with decrease in ESS on therapy recorded. 
Restless Leg Syndrome 
Two participants with BD, but no controls, reported moderate or severe restless legs symptoms.  
Accelerometry defined sleep/wake cycles 
Compliance with the accelerometry was very good with the mean number of nights of data collected 
being 20.1 for controls and 19.2 for the BD group. Accelerometry measures showed participants with 
BD to spend significantly longer time in bed, have significantly longer nocturnal sleep time and also 
more unstable and variable sleep wake patterns, alongside longer daytime napping periods, than 
those in the control group (see Table 2). Compared to controls participants with BD spent around 51 
minutes per night longer in bed, spent 24 mins longer asleep at night and had lower sleep efficiency. 
Daytime napping/sedentary behaviour was also on average significantly longer by 29 mins/day in 
participants with BD. The relative amplitude between the most active 10 hours and least active 5 
hours was significantly lower in the participants with BD than the controls driven primarily by 
significantly lower M10 activity. The intra-subject variability in all sleep variables was significantly 
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greater in the participants with BD, indicating instability in sleep/wake patterns compared to 
controls. 
Visual representations of typical actograms are shown in figure 1. The actograms could clearly 
distinguish different sleep wake patterns. Using the definitions as described above 23 of the BD 
patients had normal sleep and 23 had abnormal sleep length or CRD. Four (2.2%) were short 
nocturnal sleepers <6hours and 14 (30.4%) were long sleepers >10 hours over each 24 hour period.  
Within the long sleepers, this included daytime naps. Twelve (26.1%) had CRD including delayed 
sleep phase pattern (n=3), advanced sleep phase pattern (n=1), irregular sleep/wake phase (n=3) 
non-24 hour sleep/wake phase disorder (n=4) and circadian sleep-wake disorder not otherwise 
specified (n=1). This compared with just four control participants with CRD, one with an advanced 
sleep phase and three with delayed sleep phase.  There was significant overlap between the various 
sleep patterns and circadian dysrythmia as shown in figure 2.  Two of the four BD patients who were 
short sleepers and 6 of the 14 long sleepers also had evidence of CRD.  OSA was also a potential 
explanation of long sleep in 5 patients with BD.  
Melatonin assays 
Thirty nine controls and 38 BD participants provided at least one urine collection that had a clear 
melatonin rhythm assessed with cosinor analysis.  An additional 2 participants with BD provided 
good samples but had a 24 hour aMT6s output that was too low to detect a rhythm (<3µg/24 hours). 
Fifty seven (n=30 controls; n=27 BD) participants provided 2 urine samples allowing a period to be 
calculated. Two participants in the control group and 5 BD participants had a non-24 hour melatonin 
period (defined as > 24.2 hours or < 23.8 hours). Controls demonstrated a significantly greater 
aMT6s secretion( μg/24 hours)  than the BD group (18.0 (SD=9.1) vs 12.8 (SD=8.5); Mann-Whitney; 
476.0; p=0.003), a greater mesor (µg) (rhythm adjusted mean), controls 12.1 (SD 6.1) vs BD 9.0 (SD 
6.0); t=2.56 (75), p=0.012 and amplitude (µg), controls 14.5 (SD 8.0) vs. BD 9.8 (SD 7.7); t= 3.03 (75), 
p=0.003. Control participants also differed from BD participants in that they demonstrated a 
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significantly earlier mean acrophase (hours)(time of peak aMT6s concentration) which was on 
average 1 hour 26 minutes earlier, controls 3.24 (SD=1.88) vs BD 4.67 (SD=2.23); Mann-Whitney U; 
476.0, p=0.004). The later acrophase in the BD group is indicative of a delayed biological rhythm 
compared to the controls, in keeping with the larger number of evening chronotypes in the BD group 
(see Table 1).  
Comparison of mood, sleep, function, QoL and melatonin in normal and abnormal sleeping BD 
patients.   
Differences in mood, anxiety, psychosocial function and QoL were explored within the BD group 
comparing those with accelerometer defined normal (n=23) and abnormal sleep (n=23) (table 3). 
There were no statistically significant differences in age, BMI, numbers with OSA or mean AHI, mood 
or anxiety between the groups. Abnormal sleepers subjectively rated their sleep as lower quality 
than normal sleepers on the PSQI although it is noteworthy that normal sleeping BD participants still 
scored in the clinically significant range for poor sleep quality(>5).  BRIAN scores were also 
significantly greater in abnormal compared to normal sleepers indicating greater difficulty 
maintaining good 24 hour rhythms.  However, there was no significant difference in daytime 
sleepiness scores measured on the ESS with both groups scoring in the normal range (ESS < 10).   
While mood ratings did not differ between normal and abnormal sleeping groups, there was a 
significant correlation between both HAMD17 and BDI scores (with sleep items removed) and PSQI 
total score in the BD group (Spearmans rank order correlation r2(46) = 0.413, p<0.004 r2(46) = 0.529, 
p<0.001 respectively), though no correlation between objective actigraphy measures and mood.  
There was, however, significantly poorer psychosocial functioning (t-test; 3.033; p<0.004) and lower 
QoL (t-test; -2.495; p=0.016) in abnormal versus normal sleeping patients with BD.  These 
differences remained when covarying for either HAMD17 (FAST, F=6.502 df = 1,43,  p=0.014; 
QoL.BD, F=6.436 df= 1, 43, p=0.015) or BDI (FAST, F = 7.527, p=0.009;  QoL.BD, F=8.839, p=0.005). 
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Therefore abnormal sleep identified with actigraphy was associated with reduced function and QoL 
independently from mood.  
The aMT6s 24 hour secretion also differed significantly within the BD group. BD participants with 
normal sleeping patterns demonstrated significantly greater 24 hour aMT6s secretion than abnormal 
sleeping participants (table 2), but did not differ from normal sleeping controls (BD 15.8 (SD 9.1) vs 
controls 17.5 (8.3) (Mann-Whitney U 266.0; p=0.367).  
The possible role of medication in sleep phenotype was explored. Significantly more long sleepers 
(42.9%) took hypnotics than normal sleepers (6.3%). Fisher’s exact test p=0.031. There were no 
other significant differences in the medications between subgroups of patients. We did assess 
whether age of patient correlated with sleep-wake pattern. Abnormal sleepers were older than 
normal BD sleepers 49 years vs 43years p=0.029. The BD patients with OSA were older than normal 
BD sleepers 51 years vs 44 years p=0.054. Otherwise there were no significant differences in age 
between normal sleepers and long sleepers or normal sleepers and CRD sleepers. 
 
Discussion 
This is the most comprehensive study to date to assess sleep and circadian rhythm in patients with 
BD compared to controls.  Of the patients with objective measures of abnormal sleep, a high 
proportion had CRD (26.1%) and there was considerable overlap between different sleep and 
circadian rhythm phenotypes.  Abnormality in circadian rhythm in BD was further demonstrated in 
the BD group by significant differences in melatonin secretion compared to healthy controls, 
particularly a decreased 24 hour output seen in the patients with abnormal sleep patterns.  Those 
BD patients with abnormal sleep had similar mood symptoms to those with normal sleep but less 
stable biological rhythms, worse psychosocial functioning and reduced QoL.   
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The patients with BD in our study spent longer in bed, had more fragmented sleep and had more 
unstable and irregular sleep wake patterns. However we were also able to show different sleep 
phenotypes within individual participants. It was possible to determine that within the BD group, 23 
retained normal sleep wake patterns with a stable circadian rhythm and total sleep time between 6 
and 10 hours. However 23 had clearly abnormal sleep with striking circadian dysrhythmia in 12 of 
the patients.  Although a number of previous studies have reported different patterns of sleep 
disturbance in BD, these have usually relied on only short periods of sleep diary or accelerometry 
data to assess the sleep/wake cycle.  Two different studies, each with just 19 BD patients compared 
group actigraphy variables over periods of 5 and 7 days respectively with controls, but did not define 
different sleep phenotypes between individual BD subjects and simply reported mean activity levels 
(Jones et al., 2005, Millar et al., 2004).  One problem with the detection of CRD is that patients may 
appear to have either an insomnia or hypersomnia pattern if the period of recording is too short and 
this is particularly true of a non-24 hour period disorder.  The recently revised ICSD-3 diagnostic 
criteria for this disorder stipulate at least 2 weeks of sleep logs and accelerometry should be 
performed to make the diagnosis alongside clinical interview (American Academy of Sleep Medicine, 
2014).  Our data also supports this view given the high rate of patients with subjective descriptions 
of insomnia (as captured by the HAMD sleep items) while objective accelerometry data showed a 
low rate of short sleepers. Nine of the 12 patients who had  CRD scored the maximum of 2 on at 
least one of the HAMD sleep items suggesting many of the patients complaining of ‘insomnia’ 
actually have  CRD.   
There is increasing evidence for an intrinsic circadian rhythm dysfunction within a number of 
psychiatric disorders and some previous studies of melatonin levels in BD patients have shown 
reduced melatonin compared to controls as well as a later onset, although others have not shown 
any difference in light suppression response compared to controls(Beck-Friis et al., 1984, Kennedy et 
al., 1996, Lam et al., 1990, Novakova et al., 2015, Nurnberger et al., 2000, Robillard et al., 2013, 
Souetre et al., 1989). Repeated measurements are required to look at the period to estimate 
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whether it is near 24 or longer as previous studies have not reported this. In our study, between 
group comparison of patients and controls showed both reduced melatonin output and a delayed 
acrophase (time of peak melatonin concentration) within BD compared to controls. However the 
differences were most marked in those BD patients with abnormal sleep and/or circadian rhythm 
where total amount of melatonin was significantly lower than BD patients with normal sleep wake 
rhythms. There could be a number of potential reasons. Those with fragmented sleep may have 
abnormal light exposure in rooms with increased light levels or have light on during the night that 
suppresses melatonin output. Alternatively, a subset of BD patients could have an intrinsic circadian 
rhythm abnormality although all the controls and the majority of patients with BD had a normal 
pattern and timing of melatonin secretion, even some with abnormal accelerometry data. Some of 
those who reported fragmented night sleep had very low melatonin levels of <3ug/ml and this may 
provide a mechanistic explanation for the failure to consolidate night sleep for some and this may 
provide a therapeutic target. We looked for but did not find evidence that mood stabilising 
medication such as lithium affected the circadian rhythm, those on hypnotics had longer sleep time 
but this might simply reflect the drugs effect.  
Overnight respiratory sleep studies analysis showed mild or moderately severe OSA in 29% of 
patients with BD compared to 10% of controls. There is increasing recognition that secondary 
consequences of inactivity, weight gain and metabolic syndrome possibly related to medication all 
increase the risk of conditions such as OSA in those with psychiatric disease.  As expected the BD 
group had an increased BMI compared to the control group.  OSA will fragment night sleep and 
contribute to daytime sleepiness, sedentary behaviour and potentially hypersomnia.  Indeed nearly 
half of the patients with OSA were also rated as long sleepers.  Three of the 12 BD patients with OSA 
were prescribed hypnotics and these patients had a longer mean nocturnal sleep duration (8.9 vs. 
7.7 hours) and 24 hour sleep duration (11.3 vs. 9.7 hours) than those not prescribed hypnotics. It is 
possible that undiagnosed OSA may lead to the misdiagnosis of other sleep disorders such as 
insomnia and lead to inappropriate prescription of hypnotics which may excessively prolong both 
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nocturnal and daytime sleep and may be at least partially responsible for the increased prevalence 
of long sleepers in this study. While the sample of patients with BD was not an epidemiological one, 
the prevalence of OSA of 29% in our sample, is consistent with previous research (Kelly et al., 2013, 
Soreca et al., 2015) and highlights the need for screening and treatment of OSA in this patient group 
given the association between OSA and serious cardiovascular morbidity (Butt et al., 2010).  
Those participants with BD with any cause of abnormal sleep had significantly worse psychosocial 
functioning and quality of life compared to those with normal sleep. The differences between groups 
remained after covarying for depressed mood suggesting that accelerometry defined abnormal sleep 
was associated with lower function and QoL independently of mood.  Although we found a 
moderate correlation between mood and subjective sleep quality measured on the PSQI we found 
no differences in mood scores between the groups of normal and abnormal BD sleepers. This may 
be because subjective and objective assessments measure different dimensions of sleep. Other 
studies have however found associations between disturbed sleep and mood (Eidelman et al., 2010, 
Talbot et al., 2012) but both these studies used sleep diaries to assess sleep function whereas in this 
study we classified normal and abnormal sleep using accelerometry which may account for the 
difference in findings.   
The impact of targeting specific sleep problems therapeutically on the course of BD needs to be 
examined further. A preliminary randomised controlled trial assessed the effects of cognitive 
behavioural therapy for insomnia in patients with BD and shown that not only was it possible to 
improve sleep efficiency and decrease the severity of insomnia, but time in episode of mood 
disturbance decreased (Harvey et al., 2015).  
Strengths of the study include a well characterised group, multiple measures of mood and 
comprehensive measures of sleep and circadian rhythm across 21 days. The use of a triaxial 
accelerometer that records acceleration in SI units rather than brand specific activity counts and the 
fact that the raw accelerometry data was analysed on an open access algorithm meaning future data 
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sets recorded in SI units can use identical analysis methodology thereby making different datasets 
directly comparable. 
Weaknesses of the study include a lack of the gold standard measure of sleep using video 
polysomnography. However this was a field study and it was felt that studying patients with partial 
polysomnography in their own homes would increase compliance and the main aim of the home 
sleep study was to screen for all forms of sleep disordered breathing. The sample was opportunistic 
with a potential bias for over-representation of patients with BD and sleep disorders, while controls 
were screened out if they suffered significant sleep problems.  A larger, more representative, sample 
size would have allowed more accurate assessment of the prevalence of sleep and circadian 
disorders as well as greater sub group analysis of the differential effect of the different patterns of 
sleep and circadian rhythm. . Future studies might include those with other psychiatric disorders or 
control subjects with primary sleep disorders to study the impact upon cognition. 
In conclusion we have found that many patients with BD that have sleep disorders have  CRD and/or 
OSA.  BD participants with abnormal sleep had lower function and quality of life which was not 
accounted for by lower mood. Abnormal sleep in BD is also characterised by reduced 24 hour 
melatonin secretion compared to both healthy controls and those with BD and normal sleep. There 
is a need for the use of objective markers of the sleep wake cycle and respiratory function to 
accurately determine different sleep patterns within clinical populations and assess the impact of 
specific therapies targeted at these sleep and circadian disorders on long term outcomes of the 
psychiatric disorders. 
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 Table 1. Characteristics of Participants 
   Test Statistics 
 Controls 
(n=42) 
Bipolar 
Disorder 
(n=46) 
Χ2 (df) Mann 
Whitney 
U 
p 
Female Gender n (%) 29 (69) 31 (67.4) 0.028 
(1) 
 0.868 
Age years: mean (SD) 
(Range) 
42.5 (11.9) 
(19-64) 
46.8 (11.1) 
(23-64) 
 768.0  0.098 
BMI  mean: kg/m2 (SD) 
(Range) 
25.6 (4.8) 
(19.5-39.7) 
30.0 (6.7) 
(21.0-52.0) 
 538.0 0.001 
Currently Employed, n (%) 34 (81) 23 (50) 9.218 
(1) 
 0.002 
Chronotype n (%) 
Morning 
Evening 
Neither Type 
 
19 (45.2) 
3 (7.1) 
20 (47.6) 
 
14 (30.4) 
10 (21.7) 
22 (47.8) 
 
4.449 
(2) 
  
0.108 
HAM-D17 mean (SD) 0.3 (0.6)  9.1 (7.2)  49.0 <0.001 
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(Range)  (0-2) (0-35) 
HAM-D without sleep 
items mean (SD) 
(Range) 
0.24 (0.53) 
(0-2) 
7.0 (6.2) 
(0-30) 
 59.0 <0.001 
BDI (SD)  
(Range) 
0.6 (1.6)  
(0-9) 
12.2 (11.5) 
(0-49) 
 127.5 <0.001 
BDI without sleep item 
mean (SD) 
(Range) 
0.6 (1.6) 
(0-9) 
11.3 (11.1) 
(0-47) 
 169.0 <0.001 
YMRS mean (SD) 
(Range) 
0.1 (0.4) 
(0-2) 
0.9 (2.2) 
(0-10) 
 839.0 0.075 
STAI-S (SD) 
(Range) 
23.6 (4.0) 
(20-34) 
35.1 (12.8) 
(20-73) 
 345.5 p<0.001 
STAI-T 
(Range) 
24.6 (7.1) 
(20-54) 
44.0 (14.7) 
(21-77) 
 206.0 p<0.001 
PSQI Global score mean 
(SD) 
(Range) 
2.2 (1.3) 
(0-4) 
8.6 (4.6) 
(1-18) 
 138.5 <0.001 
ESS mean (SD) 
(Range) 
3.8 (2.5) 
(0-9) 
6.2 (4.9) 
(0-21) 
 680.5 0.016 
BRIAN mean (SD) 
(Range) 
20.4 (3.2) 
(18-30) 
40.1 (13.6) 
(18-65) 
 122.500 <0.001 
FAST mean (SD) 
(Range) 
3.9 (6.2) 
(0-22) 
23.2 (17.4) 
(0-72) 
 211.500 <0.001 
QoL.BD mean (SD) 
Range  
215.3 (20.2) 
(162-263) 
157.7 (39.5) 
(50-235) 
 167.500 <0.001 
 
SD = Standard Deviation, df = degrees of freedom, BMI = body mass index, HAM-D17 = 17 item 
Hamilton Depression Rating Scale, BDI = Beck Depression Inventory, YMRS = Young Mania Rating 
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Scale, STAI- S/T = State and Trait Anxiety Inventory- State/Trait, PSQI = Pittsburgh Sleep Quality 
Index, ESS = Epworth Sleepiness Scale, BRIAN = Biological Rhythms Interview of Assessment in 
Neuropsychiatry, FAST = Functional Assessment Short Test, Qol.BD = Quality of Life in Bipolar 
Disorder Questionnaire Morning and evening chronotypes include both definite and moderate 
subtypes.  
 
Table 2. Summary Accelerometer Data 
   Test Statistic 
 Controls 
(n=42) 
Bipolar 
Disorder 
(n=46) 
t-test (df) Mann 
Whitney 
U 
p 
TIB hours (SD) 7.85 (0.77) 8.69 (1.48)  562.000 0.001 
Intra-subject variability in 
TIB 
1.19 1.72 -3.016 (86)  0.003 
Nocturnal sleep time (SD) 6.92 (0.70) 7.33 (1.20)  664.000 0.012 
Intra-subject variability in 
nocturnal sleep time 
1.01 1.40 -3.386 (86)  0.001 
Sleep efficiency (SD) 0.88 (0.04) 0.85 (0.75)  707.000 0.030 
Intra-subject variability in 
sleep efficiency 
0.049 0.069 -2.960 (86)  0.004 
Daytime naps/sedentary 
behaviour (SD) 
1.47 (0.86) 1.95 (1.05) -2.246 (86)  0.027 
Intra-subject variability in 
daytime naps/ sedentary 
behaviour 
0.86 1.10 -2.336 (86)  0.022 
Intra-subject variability in 
sleep onset time (hours) 
0.99 1.42  730.000 0.056 
Intra-subject variability in 
sleep offset time (hours) 
1.29 2.24  694.000 0.023 
L5 (SD) 6.0 (2.8) 5.9 (1.9)   923.000 0.719 
M10 (SD) 47.8 (14.8) 37.8 (11.6) 3.508 (86)  0.001 
Relative amplitude 
between day and night 
0.77 (0.10) 0.71 (0.13)  698.000 0.025 
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activity (SD) (M10-L5) 
Mean acceleration (milli g) 
(SD) per 24 hours 
30.77 (9.1) 23.77 (6.6) 4.119  <0.001 
 
TIB = time in bed, Intra-subject variability in sleep variables was defined by the between night 
standard deviation over the assessment period for each subject, daytime naps/sedentary behaviour 
is the sum of all time epochs that meet the algorithm defined sleep criteria but are outside of the 
nocturnal time window defined by the sleep diary, L5 = mean acceleration over the least active 5 
hour window in each 24 hour period, M10 = mean acceleration in the most active 10 hour window in 
each 24 hour period.   
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Table 3. BD normal versus abnormal sleepers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI = body mass 
index, AHI = 
apnoea hypopnoea 
index, PSQI = 
Pittsburgh Sleep 
Quality Index, ESS 
= Epworth 
Sleepiness Scale, 
BRIAN = Biological 
Rhythms Interview 
of Assessment in 
Neuropsychiatry, 
 
 
Bipolar 
normal 
sleeper 
(n=23) 
Bipolar 
abnormal 
sleeper 
(n=23) 
Normal vs. abnormal test 
statistics  
 Mean (SD) Mean 
(SD) 
t (df) Mann 
Whitney 
U 
p 
Age (years)  45.6 (11.0)  47.9 
(11.2)  
 229.5 0.441 
BMI (Kg/m2)  28.4 (4.5) 31.5 (8.1) 1.199 (44)  0.170 
AHI  6.3 (8.7) 4.3 (5.0)  198.0 0.754 
HAMD17 7.8 (7.0) 10.4 (7.3) 1.659 (44)  0.104 
BDI 10.0 (11.3) 14.4 
(11.6) 
1.770 (44)  0.084 
YMRS 1.4 (2.8) 0.4 (1.3)  225.5 0.216 
STAI-S 33.2 (14.4) 37.0 
(10.9) 
1.386 (44)  0.173 
STAI-T 40.5 (13.8) 47.3 
(14.8) 
1.611 (44)  0.114 
PSQI  6.9 (3.4) 10.4 (5.0) 2.733 (44)  0.009 
ESS 5.6 (3.7) 6.9 (5.8) 0.643(44)  0.524 
BRIAN 35.7 (13.6) 44.5 
(12.3) 
2.285 (44)  0.027 
FAST 16.7 (15.7) 29.7 
(16.8) 
3.033 (44)  0.004 
QoL.BD 171.4 (37.9) 143.9 
(36.9) 
-2.495 
(44) 
 0.016 
Melatonin (normal sleeper n=19, abnormal sleepers n=21).  
aMT6s 
(µg/24hr) 
15.8 (9.1) 10.0 (7.0)  108.0 0.013 
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FAST = Functional Assessment Short Test, Qol.BD = Quality of Life in Bipolar Disorder Questionnaire, 
HAMD17 = Hamilton Depression Rating Scale 17 item, BDI = Beck Depression Inventory, YMRS = 
Young Mania Rating Scale, ASRMS = Altman Self Rating Mania Scale, STAI-S/T = State and Trait 
Anxiety Inventory – State/trait, aMT6s = 6-sulphatoxymelatonin.  
 
 
 
Figure 1. Legend 
Actograms demonstrating the sleep wake cycle over 21 days and timing of aMT6s acrophase from 
6 different sleep phenotypes. Actigraphic data are 48 h double-plotted with successive days on 
vertical axis starting at midday. 
The diamonds represent the timing of the acrophase of aMT6s taken at two different time points 
over the 21 days of actigraphy. This is a marker for the phase of the circadian clock 
(a) Normal sleeper with a well entrained circadian rhythm. Mean nocturnal sleep duration = 6.9 
hours. 
(b) Short sleeper with a well entrained circadian rhythm. Mean sleep duration = 5.76 hours.   
(c) Long sleeper mean sleep duration = 10.95 hours. Note mildly irregular sleep/wake times and 
aMT6s period length =24.40 hours. 
(d) Advanced sleep phase with well entrained circadian rhythm. Mean sleep onset time = 20.25, 
mean nocturnal sleep duration = 7.23 hours.  
(e) Delayed sleep phase with well entrained circadian rhythm. Mean sleep onset time = 01:43, 
mean nocturnal sleep duration = 08:59 hours.  
(f) Non 24 hour sleep-wake rhythm. Actogram demonstrated an irregular sleep/wake cycle with 
evidence of free running sleep onset during the final 8 days. aMT6s period length = 24.40 
hours.  
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Figure 2. Legend  
Sleep phenotypes and their overlap in the BD group.  
Normal sleepers = >6 & < 10 hours nocturnal sleep and no CRSD; Long sleepers = total 24 hour sleep 
> 10 hours; Short sleepers = nocturnal sleep < 6hours; CRSD = circadian rhythm sleep disorder; OSA = 
obstructive sleep apnoea.  
*3 of the participants in the long sleep only cohort and 2 of the normal sleepers did not complete the 
test for sleep apnoea.  
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Fig. 2 
 
 
 
 
 
